Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice

Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice

The survival of most patients with advanced stage non-small cell lung cancer is prolonged by several months when they are treated with first- and next-generation inhibitors targeting <i>ALK </i>rearrangements, but resistance inevitably emerges. Some of the mechanisms of resistance are se...

Full description

Bibliographic Details
Main Author: Paul Hofman
Format: Article
Language:English
Published: MDPI AG 2021-01-01
Series:Cells
Subjects:
liquid biopsy
lung cancer
<i>ALK</i>
resistance
targeted therapy
Online Access:https://www.mdpi.com/2073-4409/10/1/168
id doaj-e49440a003fa429eab7f6d2237d60a61
record_format Article
spelling doaj-e49440a003fa429eab7f6d2237d60a612021-01-16T00:05:31ZengMDPI AGCells2073-44092021-01-011016816810.3390/cells10010168Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine PracticePaul Hofman0Laboratory of Clinical and Experimental Pathology, Université Côte d’Azur, CHU Nice, FHU OncoAge, Pasteur Hospital, 30 avenue de la voie romaine, BP69, CEDEX 01, 06001 Nice, FranceThe survival of most patients with advanced stage non-small cell lung cancer is prolonged by several months when they are treated with first- and next-generation inhibitors targeting <i>ALK </i>rearrangements, but resistance inevitably emerges. Some of the mechanisms of resistance are sensitive to novel ALK inhibitors but after an initial tumor response, more or less long-term resistance sets in. Therefore, to adapt treatment it is necessary to repeat biological sampling over time to look for different mechanisms of resistance. To this aim it is essential to obtain liquid and/or tissue biopsies to detect therapeutic targets, in particular for the analysis of different genomic alterations. This review discusses the mechanisms of resistance to therapeutics targeting genomic alterations in <i>ALK</i> as well as the advantages and the limitations of liquid biopsies for their identification.https://www.mdpi.com/2073-4409/10/1/168liquid biopsylung cancer<i>ALK</i>resistancetargeted therapy
collection DOAJ
language English
format Article
sources DOAJ
author Paul Hofman
spellingShingle Paul Hofman
Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
Cells
liquid biopsy
lung cancer
<i>ALK</i>
resistance
targeted therapy
author_facet Paul Hofman
author_sort Paul Hofman
title Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
title_short Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
title_full Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
title_fullStr Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
title_full_unstemmed Detecting Resistance to Therapeutic ALK Inhibitors in Tumor Tissue and Liquid Biopsy Markers: An Update to a Clinical Routine Practice
title_sort detecting resistance to therapeutic alk inhibitors in tumor tissue and liquid biopsy markers: an update to a clinical routine practice
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2021-01-01
description The survival of most patients with advanced stage non-small cell lung cancer is prolonged by several months when they are treated with first- and next-generation inhibitors targeting <i>ALK </i>rearrangements, but resistance inevitably emerges. Some of the mechanisms of resistance are sensitive to novel ALK inhibitors but after an initial tumor response, more or less long-term resistance sets in. Therefore, to adapt treatment it is necessary to repeat biological sampling over time to look for different mechanisms of resistance. To this aim it is essential to obtain liquid and/or tissue biopsies to detect therapeutic targets, in particular for the analysis of different genomic alterations. This review discusses the mechanisms of resistance to therapeutics targeting genomic alterations in <i>ALK</i> as well as the advantages and the limitations of liquid biopsies for their identification.
topic liquid biopsy
lung cancer
<i>ALK</i>
resistance
targeted therapy
url https://www.mdpi.com/2073-4409/10/1/168
work_keys_str_mv AT paulhofman detectingresistancetotherapeuticalkinhibitorsintumortissueandliquidbiopsymarkersanupdatetoaclinicalroutinepractice
_version_ 1724336188202942464

Similar Items